TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04409132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
Study: NCT00635193

Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal Doxorubicin
Description: 40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.

Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal Doxorubicin
Description: 40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.

Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal Doxorubicin
Description: 40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.

Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal Doxorubicin
Description: 40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.

Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal Doxorubicin
Description: 40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.

Intervention type: DRUG
Group type: OTHER
Intervention: M200 (Volociximab)
Description: 15 mg/kg, IV infusions every week until disease progression

Intervention type: DRUG
Group type: OTHER
Intervention: M200 (Volociximab)
Description: 15 mg/kg, IV infusions every week until disease progression

Intervention type: DRUG
Group type: OTHER
Intervention: M200 (Volociximab)
Description: 15 mg/kg, IV infustions every other week until disease progression
Study: NCT05726617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avatar Intervention
Description: 8 weekly sessions of 60 minutes.
Study: NCT03808480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA and Nivolumab
Description: Cyclophosphamide 500mg/m2 IV on D1 (C1-4), 1cycle=21days) Doxorubicin 50mg/m2 IV on D1 (C1\~4, 1cycle=21days) Nivolumab 360 mg/IV C2\~4 D1 (1cycle=21days) Nivolumab 400mg/IV on D1 from Cycle 5 every 4 weeks.
Study: NCT01308385

Intervention type: OTHER
Intervention: Conditioned pain modulation
Description: When evaluating conditioned pain modulation, pressure pain threshold in the musculus quadriceps femoris act as test stimulus and 2 minutes cold pressor test (stirred ice and water) acts as the conditioning stimulus. The difference between pain thresholds before and after the cold pressor test is defined as the effect of CPM.
Study: NCT04084652

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mycoprotein ingestion
Description: The ingestion of mycoprotein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mycoprotein ingestion
Description: The ingestion of mycoprotein
Study: NCT04027582

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: didactic teaching and simulator practice
Description: the trainee will undergo didactic teaching on fiber-optic intubation followed by hands on practice on their assigned simulator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: didactic teaching and simulator practice
Description: the trainee will undergo didactic teaching on fiber-optic intubation followed by hands on practice on their assigned simulator
Study: NCT01391260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Radiation Therapy: 3D-CRT/IMRT 95%PTV 60-66Gy, 1.8-2.0Gy/f,5f/w; Gefitinib: 250 mg, Qd, p.o;
Study: NCT04308668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
Study: NCT04085926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sealed therapeutic shoe
Description: Off-the-shelf therapeutic shoe and custom-made insole

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total contact cast
Description: Custom-made total contact cast
Study: NCT03563989

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of Stent (PCI)
Description: Treatment of CTO with Percutaneous Coronary Intervention (PCI) Patients are randomized to receive either self-expandable stent or balloon expandable stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of Stent (PCI)
Description: Treatment of CTO with Percutaneous Coronary Intervention (PCI) Patients are randomized to receive either self-expandable stent or balloon expandable stent
Study: NCT03693846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV infusion per institutional guidelines and the Package Insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV infusion per institutional guidelines and the Package Insert
Study: NCT03806166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shorter Systemic Antibiotics
Description: Reduced duration of post-operative systemic antibiotic therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard duration of systemic antibiotic treatment
Study: NCT04485871

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: Triple Strength Omega-3 from Webber Naturals; 4 oral softgels (600 mg EPA and 300 mg DHA / softgel)
Study: NCT02584504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
Study: NCT01870895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM060
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT03588143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Two kinds of electrical stimulation (TENS and HVPS) and placebo intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation
Description: Two kinds of electrical stimulation (TENS and HVPS) and placebo intervention

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electrical stimulation
Description: Two kinds of electrical stimulation (TENS and HVPS) and placebo intervention
Study: NCT02000791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparison of fibreoptic view

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of fibreoptic view
Study: NCT00528047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRLX 93936
Description: PRLX 93936 will be administered intravenously over one hour daily for 5 days.
Study: NCT01207180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone call follow-up
Description: A nurse will call the patient to counsel patients on their medications and following up with their primary care provider.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Satisfaction survey
Description: Patients will be given a satisfaction survey.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group --- no intervention
Description: Control group
Study: NCT02769910

Intervention type: DRUG
Group type: OTHER
Intervention: Capsaicin 1 Hour
Description: Dermal patches for transdermal application of Capsaicin, applied for 1 hour

Intervention type: DRUG
Group type: OTHER
Intervention: Capsaicin 1 Hour
Description: Dermal patches for transdermal application of Capsaicin, applied for 1 hour

Intervention type: OTHER
Group type: OTHER
Intervention: Qutenza Demo Patch
Description: Dermal patches mimicking active Qutenza patches. Used as control in comparison of Capsaicin efficacy. Applied for 24 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: Qutenza Demo Patch
Description: Dermal patches mimicking active Qutenza patches. Used as control in comparison of Capsaicin efficacy. Applied for 24 hours.
Study: NCT03876119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraarterial alteplase
Description: See arm/group descriptions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm/group descriptions.
Study: NCT00193206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound Paclitaxel
Description: ABI-007 175 mg/m2 D1 q 14 days x 6 cycles
Study: NCT03067389

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: Genetic diagnostic test

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: Genetic diagnostic test
Study: NCT01694147

Intervention type: DEVICE
Intervention: PiCCO monitoring system
Description: The EVLW measurement will be based on transpulmonary thermodilution method. This method was recently introduced as part of the PiCCO plus system (Pulsion Medical System, Munich, Germany), for monitoring severe sepsis patients being treated in medical ICUs. This method only used a single indicator (cold saline solution), and demonstrated a satisfactory correlation with the gravimetric method. A 4-F arterial catheter (PulsiocathPV2014L16; Pulsion Medical Systems, Munich, Germany) was positioned in the descending aorta via the femoral artery using the Seldinger technique. The femoral arterial catheter and a standard central venous catheter were connected to pressure transducers, and also to an integrated bedside monitor (PiCCO; Pulsion Medical Systems).
Study: NCT01633658

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: a single dose of 2500 micrograms of cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25(OH)D
Description: a single dose of 625 micrograms of 25(OH)D
Study: NCT02595255

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01189695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir
Description: Lopinavir/ritonavir 200/50 mg every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir-boosted lopinavir
Description: Lopinavir/ritonavir 200/50 mg every 12 hours
Study: NCT03158532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin I
Description: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin I
Description: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo I
Description: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo I
Description: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin II
Description: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin II
Description: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo II
Description: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo II
Description: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
Study: NCT04387396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise specific to knee osteoarthritis.
Study: NCT04424758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video information about mammography screening
Description: A video informing about mammography screening

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Video information about smart energy systems
Description: A video informing about smart energy systems
Study: NCT03844048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: oral; film-coated tablets or tablets for oral suspension
Study: NCT01189695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: optimized background regimens (OBRs)
Description: Optimized background regimens such as NRTIs, etravirine or raltegravir
Study: NCT04393259

Intervention type: OTHER
Intervention: Rainbow Clinic Model of Antenatal Care
Description: Rainbow Clinic Model is an antenatal model of care with initial ultrasound scan at 23 weeks' gestation including uterine artery Doppler, frequency of subsequent scans determined using data from this initial scan. Continuity of care is provided by obstetricians and midwives.
Study: NCT02276274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-322-MET
Description: Oral administration of SYR-322-MET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-322-MET
Description: Oral administration of SYR-322-MET
Study: NCT00105690

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telemedicine intervention
Study: NCT03911401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% OPA-15406
Description: Twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% OPA-15406
Description: Twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Twice daily
Study: NCT03339999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-242428
Description: AGN-242428 administered as an oral capsule(s) once daily.
Study: NCT00785499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Milk Components and Metabolic syndrome
Description: 1 liter per day of the test drinks for 3 mo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Milk Components and Metabolic syndrome
Description: 1 liter per day of the test drinks for 3 mo
Study: NCT03339999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-242428
Description: AGN-242428 administered as an oral capsule(s) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-242428
Description: AGN-242428 administered as an oral capsule(s) once daily.
Study: NCT03081871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-led cardiovascular risk service (CVRS)
Description: CVRS pharmacists will access the study database including patient baseline information obtained from the medical record and patient entered data to make their assessments and recommendations to onsite physicians and onsite clinical pharmacists and individualize their communication with patients. The intervention will provide patient-centered counseling and education to improve medication adherence, lifestyle modifications and/or smoking cessation. The CVRS pharmacist does not make changes to therapy independently but, rather, provides the physicians and on-site pharmacists with action plans and status updates about adherence to Guideline metrics, which should markedly reduce the gaps in guideline-concordant therapy that place patients at risk for CVD events.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-led cardiovascular risk service (CVRS)
Description: CVRS pharmacists will access the study database including patient baseline information obtained from the medical record and patient entered data to make their assessments and recommendations to onsite physicians and onsite clinical pharmacists and individualize their communication with patients. The intervention will provide patient-centered counseling and education to improve medication adherence, lifestyle modifications and/or smoking cessation. The CVRS pharmacist does not make changes to therapy independently but, rather, provides the physicians and on-site pharmacists with action plans and status updates about adherence to Guideline metrics, which should markedly reduce the gaps in guideline-concordant therapy that place patients at risk for CVD events.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile access to study Personal Health Record
Description: Only subjects assigned to the intervention arm will have access to the mobile app version of the study personal Health Record.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web access to study Personal Health Record
Description: Subjects assigned to both the intervention and control arms will have access to the standard website version of the study personal Health Record.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web access to study Personal Health Record
Description: Subjects assigned to both the intervention and control arms will have access to the standard website version of the study personal Health Record.
Study: NCT02233972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Study: NCT03339999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered as an oral capsule(s) once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as an oral capsule(s) once daily.
Study: NCT00766870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA34893
Description: Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA34893
Description: Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA34893
Description: Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period

Intervention type: DRUG
Group type: OTHER
Intervention: Venlafaxine extended release
Description: Per oral, once daily, during 8 weeks, followed by a two-week tapering period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Per oral doses, twice daily as capsules during 10 weeks
Study: NCT03081858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSD-001
Description: Administered via intravesical instillation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSD-001
Description: Administered via intravesical instillation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSD-001
Description: Administered via intravesical instillation.
Study: NCT02440490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerised cognitive training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video watching
Study: NCT01463059

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution for injection, administered as subcutaneous injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution for injection, administered as subcutaneous injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution for injection, administered as subcutaneous injections

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection, administered as subcutaneous injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olokizumab 60 mg
Description: Olokizumab 60 mg solution for injection, administered as subcutaneous injections
Study: NCT00785499

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Milk Components and Metabolic syndrome
Description: 1 liter per day of the test drinks for 3 mo
Study: NCT01463059

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olokizumab 60 mg
Description: Olokizumab 60 mg solution for injection, administered as subcutaneous injections
Study: NCT02233972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgolides Meglumine Injection
Study: NCT00785499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Milk Components and Metabolic syndrome
Description: 1 liter per day of the test drinks for 3 mo
Study: NCT01463059

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olokizumab 120 mg
Description: Olokizumab 120 mg solution for injection, administered as subcutaneous injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olokizumab 120 mg
Description: Olokizumab 120 mg solution for injection, administered as subcutaneous injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olokizumab 240 mg
Description: Olokizumab 240 mg solution for injection, administered as subcutaneous injections
Study: NCT00620126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UC Home Automated Telemanagement
Description: Weekly assessment with UC Home Automated Telemanagement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Care
Description: Routine follow up visits and as needed telephone calls and clinic visits, written action plans, educational fact sheets from the CCFA
Study: NCT02210559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: FG-3019 will be administered per dose and schedule specified in the arm group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered per dose and schedule specified in the arm group description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered per dose and schedule specified in the arm group description.
Study: NCT02132195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTH
Description: Patients will receive ACTH twice weekly for 6 months, with a 50% dose reduction allowed for side effects. The dose will be reduce by 50% at 6 months and continued for an additional 6 months.